| Company Name: | Bristol-Myers Squibb Company | | Ticker Symbol: | BMY | | | WWW Address: | www.bms.com |
| CEO: | Lamberto Andreotti | | No. of Employees: | 28,000 |
| Common Issue Type: | CS | | Business Description: | Bristol-Myers Squibb Company is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells pharmaceutical products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 46.5 |  -0.35 | - | - | 46.6 | 47.25 | 46.25 | 472171 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 76,378.7 | 1,642.6 | 0.46 | 1.16 | 1.36 | 54.2 | 3.0 | 49.57 - 30.64 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 47.17 | $ | | PE Ratio - LTM | 54.2 | |
| Market Capitalisation | 76,378.7 | mil |
| Latest Shares Outstanding | 1,642.6 | mil |
| Earnings pS (EPS) | 1.16 | $ |
| Dividend pS (DPS) | 1.36 | ¢ |
| Dividend Yield | 3.0 | % |
| Dividend Payout Ratio | 117 | % |
| Revenue per Employee | 629,321 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 1,640.0 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | 7,237 | mil |
| Domestic Sales | 10,384 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 24.20 | % |
| Gross Profit Margin | 77.4 | % |
| EBITDA Margin | 22.3 | % |
| Pre-Tax Profit Margin | 6.1 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 8.7 | % |
| Return on Equity (ROE) | 22.9 | % |
| Return on Capital Invested (ROCI) | 15.5 | % |
| Current Ratio | 1.2 | |
| Leverage Ratio (Assets/Equity) | 2.6 | |
| Interest Cover | 14.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.58 | |
| LT Debt/Total Capital | 32.0 | % |
| Working Capital pS | 1.01 | $ |
| Cash pS | 0.82 | $ |
| Book-Value pS | 8.32 | $ |
| Tangible Book-Value pS | -1.56 | $ |
| Cash Flow pS | 2.33 | $ |
| Free Cash Flow pS | -1.02 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.67 | |
| Price/Tangible Book Ratio | -30.30 | |
| Price/Cash Flow | 20.2 | |
| Price/Free Cash Flow | -46.1 | |
| P/E as % of Industry Group | 203.0 | % |
| P/E as % of Sector Segment | 292.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 03/06/2013 |
| Dividend Ex-Date | 04/02/2013 |
| Dividend Record Date | 04/04/2013 |
| Dividend Pay Date | 04/30/2013 |
| Dividend Amount | 350 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.40 |
| Current Dividend Yield | 3.0 |
| 5-Y Average Dividend Yield | 4.6 |
| Payout Ratio | 117.0 |
| 5-Y Average Payout Ratio | 74.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.7 | 100 | 132,762 | 339,565 |
| 4 Weeks | 49.57 | 43.35 | 43.30 | 8.9 | 111 | 131,715 | 2,370,873 |
| 13 Weeks | 49.57 | 38.41 | 38.96 | 21.1 | 115 | 113,454 | 7,034,173 |
| 26 Weeks | 49.57 | 31.85 | 32.73 | 44.1 | 124 | 103,250 | 12,699,709 |
| 52 Weeks | 49.57 | 30.64 | 34.23 | 37.8 | 113 | 103,230 | 25,600,981 |
| YTD | 49.57 | 32.50 | - | 44.7 | 126 | 104,467 | 11,804,800 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 47.17 | 46.94 | 43.10 | 38.18 | 36.74 | 0.46 | 0.01 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -2.11 | 27.5 | -2.52 |
| Income | -4.56 | 6.1 | -13.84 |
| Dividend | 0.33 | 0.2 | 1.21 |
| Capital Spending | 23.96 | NA | 24.74 |
| R&D | 2.83 | NA | 2.75 |
| Normalized Inc. | 8.58 | NA | 0.92 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -27.0 | -27.0 | -17.1 |
| Earnings % | 0.0 | 0.0 | -52.5 |
| EPS % | -42.2 | -42.2 | -46.3 |
| EPS $ | -0.27 | -0.27 | -1.00 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 3.46 |
| Current Ratio | 1.2 |
| Quick Ratio (Acid Test) | 0.7 |
| Liquidity Ratio (Cash) | 0.34 |
| Receivables Turnover | 5.2 |
| Average Collection Period | 69 |
| Working Capital/Equity | 9.1 |
| Working Capital pS | 0.76 |
| Cash-Flow pS | 1.95 |
| Free Cash-Flow pS | -2.06 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.05 |
| Financial Leverage Ratio (Assets/Equity) | 2.6 |
| Debt Ratio | 62.0 |
| Total Debt/Equity (Gearing Ratio) | 0.54 |
| LT Debt/Equity | 0.48 |
| LT Debt/Capital Invested | 69.3 |
| LT Debt/Total Liabilities | 29.5 |
| Interest Cover | 13.9 |
| Interest/Capital Invested | 0.66 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 65.90 |
| Tobin's Q Ratio | 2.16 |
| Current P/E Ratio - LTM | 54.20 |
| Enterprise Value (EV)/EBITDA | 20.32 |
| Enterprise Value (EV)/Free Cash Flow | -27.50 |
| Dividend Yield | 3.0 |
| Price/Tangible Book Ratio - LTM | -30.30 |
| Price/Book Ratio - LTM | 5.67 |
| Price/Cash Flow Ratio | 20.2 |
| Price/Free Cash Flow Ratio - LTM | -46.1 |
| Price/Sales Ratio | 4.78 |
| P/E Ratio (1 month ago) - LTM | 47.1 |
| P/E Ratio (26 weeks ago) - LTM | 30.0 |
| P/E Ratio (52 weeks ago) - LTM | 15.4 |
| 5-Y High P/E Ratio | 31.3 |
| 5-Y Low P/E Ratio | 6.1 |
| 5-Y Average P/E Ratio | 16.7 |
| Current P/E Ratio as % of 5-Y Average P/E | 325 |
| P/E as % of Industry Group | 203.0 |
| P/E as % of Sector Segment | 292.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 33.2 |
| PER SHARE FIGURES |
| LT Debt pS | 4.03 |
| Current Liabilities pS | 5.08 |
| Tangible Book Value pS - LTM | -1.56 |
| Book Value pS - LTM | 8.32 |
| Capital Invested pS | 12.29 |
| Cash pS - LTM | 0.82 |
| Cash Flow pS - LTM | 2.33 |
| Free Cash Flow pS - LTM | -1.02 |
| Earnings pS (EPS) | 1.16 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -19.04 |
| Free Cash Flow Margin 5YEAR AVG | -2.21 |
| Net Profit Margin | 14.2 |
| Net Profit Margin - 5YEAR AVRG. | 30.1 |
| Equity Productivity | 1.29 |
| Return on Equity (ROE) | 18.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 40.6 |
| Capital Invested Productivity | 0.87 |
| Return on Capital Invested (ROCI) | 12.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 28.7 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 7.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 18.3 |
| Gross Profit Margin | 77.4 |
| Gross Profit Margin - 5YEAR AVRG. | 76.2 |
| EBITDA Margin - LTM | 22.3 |
| EBIT Margin - LTM | 7.3 |
| Pre-Tax Profit Margin | 13.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 27.1 |
| Effective Tax Rate | -6.9 |
| Effective Tax Rate - 5YEAR AVRG. | 17.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 202 |
| Revenue per Employee | 629,321 |
| Net Income per Employee | 89,321 |
| Average Collection Period | 63 |
| Receivables Turnover | 5.2 |
| Day's Inventory Turnover Ratio | 139 |
| Inventory Turnover | 2.6 |
| Inventory/Sales | 9.4 |
| Accounts Payble/Sales | 12.50 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 14.19 |
| Fixed Assets Turnover | 0.67 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 10.64 |
| Revenue per $ Plant | 3.30 |
| Revenue per $ Common Equity | 1.29 |
| Revenue per $ Capital Invested | 0.87 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.1 |
| Research & Devlopment (R&D) as % of Revenue | 22.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 22.2 |
|
|  
| | |  |  | |
| |
